P-Gp Or Bcrp Substrates Interactions

P-gp inducers may decrease berotralstat plasma concentration, leading to reduced efficacy of ORLADEYO. Avoid concomitant use.

Source: NLP:berotralstat hydrochloride

Imlunestrant inhibits P-gp and BCRP, increasing substrate exposure and risk of adverse reactions. Avoid concomitant use unless minimal concentration changes are acceptable.

Source: NLP:imlunestrant

Concomitant use may increase repotrectinib exposure and increase incidence and severity of adverse reactions. Avoid concomitant use.

Source: NLP:repotrectinib

Coadministration increased P-gp substrate exposure, which may increase adverse reactions. Decrease substrate dosage if coadministration unavoidable and minimal concentration changes may lead to serious reactions.

Source: NLP:capmatinib

Increase mavorixafor Cmax and AUC. Monitor for adverse reactions and reduce dosage by 100 mg steps if necessary, but not below 200 mg.

Source: NLP:mavorixafor